Tyra Biosciences, Inc. TYRA Stock
Tyra Biosciences, Inc. Price Chart
Tyra Biosciences, Inc. TYRA Financial and Trading Overview
Tyra Biosciences, Inc. stock price | 7.74 USD |
Previous Close | 15.39 USD |
Open | 16.28 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 1200 |
Day's Range | 15.4 - 16.6 USD |
52 Week Range | 4.93 - 16.86 USD |
Volume | 91.73K USD |
Avg. Volume | 34.6K USD |
Market Cap | 680.99M USD |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.51 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 23 USD |
TYRA Valuation Measures
Enterprise Value | 415.86M USD |
Trailing P/E | N/A |
Forward P/E | -8.743169 |
PEG Ratio (5 yr expected) | 0.49 |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 2.7355103 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -7.156 |
Trading Information
Tyra Biosciences, Inc. Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | 204.18% |
S&P500 52-Week Change | 20.43% |
52 Week High | 16.86 USD |
52 Week Low | 4.93 USD |
50-Day Moving Average | 13.98 USD |
200-Day Moving Average | 10.46 USD |
TYRA Share Statistics
Avg. Volume (3 month) | 34.6K USD |
Avg. Daily Volume (10-Days) | 61.98K USD |
Shares Outstanding | 42.56M |
Float | 11.92M |
Short Ratio | 61.29 |
% Held by Insiders | 7.07% |
% Held by Institutions | 92.29% |
Shares Short | 1.47M |
Short % of Float | 8.32% |
Short % of Shares Outstanding | 3.45% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -13.18% |
Return on Equity (ttm) | -19.40% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -58112000 USD |
Net Income Avi to Common (ttm) | -52379000 USD |
Diluted EPS (ttm) | -1.23 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 241.7M USD |
Total Cash Per Share (mrq) | 5.68 USD |
Total Debt (mrq) | 2.59M USD |
Total Debt/Equity (mrq) | 1.04 USD |
Current Ratio (mrq) | 67.004 |
Book Value Per Share (mrq) | 5.849 |
Cash Flow Statement
Operating Cash Flow (ttm) | -51207000 USD |
Levered Free Cash Flow (ttm) | -32239876 USD |
Profile of Tyra Biosciences, Inc.
Country | United States |
State | CA |
City | Carlsbad |
Address | 2656 State Street |
ZIP | 92008 |
Phone | 619 728 4760 |
Website | https://www.tyra.bio |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 38 |
Tyra Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÅP, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies. Its lead product candidate is TYRA-300, a selective inhibitor of FGFR3 which is in Phase 1/2 clinical trial for the treatment of patients with mUC and other solid tumors. The company is also developing TYRA-300 for long-term complications associated with skeletal conditions including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes. Its product pipeline also includes TYRA-200, an FGFR1/2/3 inhibitor with potency FGFR2 fusions and molecular brake mutations for bile duct and solid tumors; FGF19+/FGFR4, a FGFR4-specific inhibitor that is active in the presence of the V550 gatekeeper and the C552 Cys mutations for liver and solid tumors; and RET, a specific inhibitor that is active in the presence of the V804 gatekeeper and the G810 solvent front mutations for the treatment of lung and thyroid cancer. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Q&A For Tyra Biosciences, Inc. Stock
What is a current TYRA stock price?
Tyra Biosciences, Inc. TYRA stock price today per share is 7.74 USD.
How to purchase Tyra Biosciences, Inc. stock?
You can buy TYRA shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Tyra Biosciences, Inc.?
The stock symbol or ticker of Tyra Biosciences, Inc. is TYRA.
Which industry does the Tyra Biosciences, Inc. company belong to?
The Tyra Biosciences, Inc. industry is Biotechnology.
How many shares does Tyra Biosciences, Inc. have in circulation?
The max supply of Tyra Biosciences, Inc. shares is 53.09M.
What is Tyra Biosciences, Inc. Price to Earnings Ratio (PE Ratio)?
Tyra Biosciences, Inc. PE Ratio is now.
What was Tyra Biosciences, Inc. earnings per share over the trailing 12 months (TTM)?
Tyra Biosciences, Inc. EPS is -1.51 USD over the trailing 12 months.
Which sector does the Tyra Biosciences, Inc. company belong to?
The Tyra Biosciences, Inc. sector is Healthcare.
Tyra Biosciences, Inc. TYRA included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
NASDAQ Global Select Market Com NQGS | 7625.89 USD — |
-5.84
|
— — | 7621.56 USD — | 7894.21 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}